Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$152.2MCash on Hand
13.9mo Cash Runway
Follow FBIOP by emailGet an email when FBIOP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about FBIOP, unsubscribe in one click. Privacy
📣 What FBIOP Says Is Next
second half of 2027 · “FB-607 is currently being studied in a randomized, placebo-controlled, Phase 2 trial for IBS-D and we expect to release top-line data in the second half of 2027.”
Company press release, Nov 13, 2026 · SEC filing
fourth quarter of 2026 · “A clinical trial evaluating MB-109, a combination CAR T cell therapy and oncolytic virus, is anticipated to initiate in the fourth quarter of 2026 for patients with IL13Rα2-positive recurrent glioblastoma and high-grade astrocytoma.”
Company press release, Aug 13, 2026 · SEC filing
in 2026 · “Avenue anticipates meeting with the FDA in 2026 to discuss and align on the design of a potential single pivotal trial for ATX-04 for Pompe disease. Financial Results: ”
Company press release, May 14, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 13, 2026 ·
Earnings Reported Q3 2026 total net revenue of $19.2 million, up about 9%, with a net loss attributable to common stockholders of $(7.9) million, or $(0.23) per share. Repaid the remaining $15.0 million under its Oaktree credit facility in full in September 2026, leaving no parent-level debt. Form 8-K · SEC filing · Press release
Oct 1, 2026 ·
Financing Fortress Biotech repaid in full the remaining $15.0 million outstanding under its Oaktree senior secured credit agreement on September 30, 2026, paying about $435,000 in accrued interest and a $150,000 prepayment fee. All liens were released and the agreement terminated. Form 8-K · SEC filing
Aug 13, 2026 ·
Earnings Fortress Biotech reported Q2 2026 total net revenue up 14% to $18.7 million and cash and cash equivalents of $196.6 million as of June 30, 2026, versus $79.4 million at year-end 2025. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
FBIOP holds $152.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $32.7M/quarter from operations,
an estimated runway of 13.9 months at that rate (BioRadar estimate, not company guidance).
Share count 82,474,127 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full FBIOP picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for FBIOP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.